IBA and the Oncology Reference Center of Aviano, Italy, sign contract to install a Proteus®ONE Proton Therapy system
19 November 2021 - 7:00AM
IBA and the Oncology Reference Center of Aviano, Italy, sign
contract to install a Proteus®ONE Proton Therapy system
Louvain-La-Neuve, Belgium, November 19,
2021 – IBA (Ion Beam Applications S.A., EURONEXT), the
world leader in particle accelerator technology and the world’s
leading provider of proton therapy solutions for the treatment of
cancer, today announces that it has signed a contract for the
installation of a Proteus®ONE1 proton therapy
turnkey solution with the Oncology Reference Center (C.R.O.) in
Aviano, Italy. IBA was selected as the preferred supplier following
a comprehensive vendor selection process. IBA expects to receive a
down payment in the coming weeks.
This Proteus®ONE, the 31st to
be sold by IBA globally, will be integrated into the current
radiotherapy department at C.R.O. and is expected to start treating
patients by the end of 2024.
Olivier Legrain, Chief Executive Officer
of IBA, commented: “We are pleased to sign this new
contract with C.R.O. to bring much needed proton therapy to cancer
patients in Italy. Securing a new proton therapy contract in Europe
demonstrates IBA’s superior market offering as well as the global
demand for this technology as we continue to see building momentum
for this treatment modality. We look forward to collaborating with
C.R.O. and welcome them to our Campus community, where they can
interact with other clinicians through the world’s first online
platform dedicated to proton therapy: www.campus-iba.com.”
***Ends***
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 1,500 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
CONTACTS
Soumya
ChandramouliChief Financial Officer+32 10
475 890Investorrelations@iba-group.com
Olivier LechienCorporate
Communication Director+32 10 475 890communication@iba-group.com
Consilium Strategic
CommunicationsAmber Fennell, Angela Gray, Lucy
Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com
1 *Proteus®ONE is a brand name of Proteus 235
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Apr 2023 bis Apr 2024